BSc MA - Cell Source Ex Chairman

CLCS Stock

USD 0.56 0.05 9.80%

Insider

BSc MA is Ex Chairman of Cell Source

Age	73
Phone	646 416 7896
Web	https://www.cell-source.com

Cell Source Management Efficiency

The company has return on total asset (ROA) of (3.7761) % which means that it has lost $3.7761 on every $100 spent on assets. This is way below average. Cell Source's management efficiency ratios could be used to measure how well Cell Source manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Cell Source to Peers

Predict price of Cell Source

Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records			INSIDER Age
	Susanne Embleton	Pharming Group NV	N/A
	Anurag Relan	Pharming Group NV	51
	Jeroen Wakkerman	Pharming Group NV	54
	Stephen Toor	Pharming Group NV	52
	Mireille MSc	Pharming Group NV	55
	Ruud Outersterp	Pharming Group NV	59
	MBA MD	Pharming Group NV	63

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people. Cell Source [CLCS] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Asset

-3.78

Cell Source Leadership Team

Elected by the shareholders, the Cell Source's board of directors comprises two types of representatives: Cell Source inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cell. The board's role is to monitor Cell Source's management team and ensure that shareholders' interests are well served. Cell Source's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cell Source's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Itamar Shimrat, CEO and President CFO, Principal Accounting Officer and Director
	BSc MA, Ex Chairman

Cell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cell Source a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-3.78
	Current Valuation	59.65 M
	Shares Outstanding	35.25 M
	Shares Owned By Insiders	32.13 %
	Price To Earning	(3.28) X
	EBITDA	(4.11 M)
	Net Income	(5.47 M)
	Cash And Equivalents	93.09 K
	Total Debt	6.5 M
	Debt To Equity	(1.04) %

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Cell OTC Stock Analysis

When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC